Drug Type Small molecule drug |
Synonyms MIK 665, MIK-665, S 64315 + [1] |
Target |
Mechanism Mcl-1 inhibitors(Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC47H44ClFN6O6S |
InChIKeyPKYIMGFMRFVOMB-UHFFFAOYSA-N |
CAS Registry1799631-75-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 2 | FR | 30 Jan 2022 | |
Hematologic Neoplasms | Phase 2 | FR | 30 Jan 2022 | |
Hematologic Neoplasms | Phase 2 | FR | 30 Jan 2022 | |
Acute Myeloid Leukemia | Phase 2 | US | 17 Feb 2021 | |
Acute Myeloid Leukemia | Phase 2 | AU | 17 Feb 2021 | |
Acute Myeloid Leukemia | Phase 2 | FR | 17 Feb 2021 | |
Acute Myeloid Leukemia | Phase 2 | ES | 17 Feb 2021 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | US | 23 Jun 2021 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | JP | 23 Jun 2021 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | BE | 23 Jun 2021 |
Phase 1/2 | 17 | MIK665+Azacitidine (50 mg S64315 (Also Referred as MIK665) With Azacitidine) | lvzerxslff(rwbfkixyim) = mwwdhohger uunorqkldk (yftbawprhc, dfayciddoe - cxurblewmv) View more | - | 06 Jun 2024 | ||
MIK665+Azacitidine (100 mg S64315 (Also Referred as MIK665) With Azacitidine) | lvzerxslff(rwbfkixyim) = mqjqeozrum uunorqkldk (yftbawprhc, blnkrxhlwt - yqfgfyladd) View more |